Diabetes News June 30th 2009

Lantus insulin: a possible link with cancer which requires further investigation
Transcript of the statement by Prof Smith and Prof Gale along with downloads of the papers (EASD)

Statement from the International Diabetes Federation – Possible Link Between Insulin Glargine and Cancer
The International Diabetes Federation today called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analogue) and increased risk of cancer (IDF)

Diabetologists try to block GP use of new diabetes drugs
Consultant diabetologists have launched an attempt to prevent GPs prescribing the newest class of type 2 diabetes drugs – subscription (Pulse, UK)

Diabetes UK’s Measure Up Roadshow is a success
Diabetes UK has so far encouraged more than 10,000 people in the UK to measure their waists and find out if they are at risk of developing Type 2 diabetes with its national Measure Up Roadshow (Diabetes UK)

New tool finds best heart disease and stroke treatments for patients with diabetes
Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke (EurelAlert)

Generex Sees Favorable Results From MetControl(tm) Chewing Gum Bio-equivalency Study Leading to Glob
Management believes the results provide convincing evidence that MetControl(tm) and Metformin tablets are therapeutically equivalent and therefore interchangeable (Generex Biotechnology Corporation)

Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazolidinediones
Also a new drug application of fixed-dose combination of alogliptin and pioglitazone HCl (generic name, tradename in Japan:Actos ®) to the Ministry of Health, Labour and Welfare in Japan (PharmaLive)

Inflammatory mediators in morbidly obese subjects; associations with glucose abnormalities and changes after oral glucose
Morbid obesity and glucose intolerance were associated with lower adiponectin levels and higher CRP levels, thus supporting a relationship between obesity, glucose homeostasis and inflammation (European Journal of Endocrinology)